Raphael Pharmaceutical (RAPH) Retained Earnings (2020 - 2025)

Raphael Pharmaceutical has disclosed Retained Earnings across 6 years of filings, most recently posting -$10.2 million for Q4 2025.

• Retained Earnings for Q4 2025 came in at -$10.2 million, down 14.39% year-over-year; the trailing twelve-month figure through Dec 2025 was -$10.2 million (down 14.39% YoY), and the FY2025 annual result was -$10.2 million, down 14.39% from the prior year.
• Retained Earnings came in at -$10.2 million for Q4 2025 at Raphael Pharmaceutical, down from -$9.9 million in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of -$2.1 million in Q3 2021 to a low of -$10.2 million in Q4 2025.
• The 5-year median for Retained Earnings is -$7.4 million (2023), against an average of -$6.8 million.
• Across the five-year window, Retained Earnings plunged 155.7% in 2021 and fell 13.48% in 2024, its largest moves.
• Raphael Pharmaceutical's Retained Earnings stood at -$2.7 million in 2021, then plunged by 125.95% to -$6.0 million in 2022, then dropped by 22.3% to -$7.4 million in 2023, then declined by 20.61% to -$8.9 million in 2024, then decreased by 14.39% to -$10.2 million in 2025.
• The last three Retained Earnings figures came in at -$10.2 million (Q4 2025), -$9.9 million (Q3 2025), and -$9.6 million (Q2 2025), per Business Quant data.